Porvair Launches Genuine 2 mL Deep Well Plate
Porvair Sciences has developed the first 96-well round deep well plate that genuinely delivers 2.00 mL liquid capacity/well in an automation compatible SLAS/ANSI footprint. The revolutionary "common wall" design provides a full 2 mL round well, round bottom well within a 45-mm height limit, thus ensuring full compatibility with most plate handling equipment.
Unlike other '2 mL' deep well plates that typically offer just 1.80–1.90 mL well, the new Porvair plate enables labs involved with fraction collecting, compound storage, plate replication and mixing applications the chance to use the full 2.00 mL well capacity without compromise.
Manufactured under class 10,000 conditions from ultra-pure grade polypropylene, Porvair's new 2.00 mL 96-well deep well plates are certified as RNase/DNase free and contain no measurable contaminants that could otherwise leach out and affect the sample. For sterile biological applications, Porvair 2.00 mL 96-well deep well plates are available irradiated. A matching thermoplastic elastomer "cap mat" provides easy friction sealing of this new plate for transport, shipping and short-term storage. For longer periods, the new 2.00 mL plate can be heat sealed using Porvair Sciences aluminium or clear heat seals together with the company's Miniseal II thermal sealer to provide a range of peelable, peirceable and re-sealable storage options.
Measuring just 45 mm high, Porvair 2.00 mL 96-well deep well plates are compatible with microplate stackers, washers and automated equipment. The new plate design incorporates features that prevent 'locking' when stacked and enable easy heat sealing.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...